Novo Nordisk bought pharmaceutical company Cardior for €1 billion – Kommersant
[ad_1]
Today, March 25, the Danish manufacturer of weight loss drugs Novo Nordisk announced on the purchase of the German pharmaceutical company Cardior Pharmaceuticals. The deal is expected to close in the second quarter and will be worth more than €1 billion. Cardior develops and produces experimental drugs for the treatment of cardiovascular diseases.
The acquisition of Cardior will help Novo Nordisk expand its activities, now the Danish company is mainly engaged in the production of diabetes and weight loss drugs Wegovy and Ozempic. Cardior’s lead drug is CDR132L for the treatment of certain heart diseases, including cardiac hypertrophy. It is currently undergoing clinical trials.
In February Novo Nordisk bought for $16.5 billion the American company Catalent, specializing in the packaging of injectable drugs.
Read about how an analogue of the drug Ozempic appeared in Russia, bypassing the Danish patent. “Pharmacies are reducing sugar”.
[ad_2]
Source link
